umu.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
BETA
Erlanson, Martin
Publikationer (10 of 25) Visa alla publikationer
Abdulla, M., Hollander, P., Pandzic, T., Mansouri, L., Ednersson, S. B., Andersson, P.-O., . . . Amini, R.-M. (2020). Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. American Journal of Hematology, 95(1), 57-67
Öppna denna publikation i ny flik eller fönster >>Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma
Visa övriga...
2020 (Engelska)Ingår i: American Journal of Hematology, ISSN 0361-8609, E-ISSN 1096-8652, Vol. 95, nr 1, s. 57-67Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.

Ort, förlag, år, upplaga, sidor
Wiley-Blackwell, 2020
Nationell ämneskategori
Hematologi
Identifikatorer
urn:nbn:se:umu:diva-165343 (URN)10.1002/ajh.25666 (DOI)000495085000001 ()31659781 (PubMedID)
Forskningsfinansiär
CancerfondenVetenskapsrådetVästerbottens läns landsting
Tillgänglig från: 2019-11-26 Skapad: 2019-11-26 Senast uppdaterad: 2020-03-23Bibliografiskt granskad
Lagerlöf, I., Holte, H., Glimelius, I., Björkholm, M., Enblad, G., Erlanson, M., . . . Molin, D. (2020). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology, 188(5), 685-691
Öppna denna publikation i ny flik eller fönster >>No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Visa övriga...
2020 (Engelska)Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 188, nr 5, s. 685-691Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended-field radiotherapy are well documented. Investigators have aimed at reducing toxicity without compromising efficacy, mainly by using combined modality treatment (CMT), i.e. chemotherapy and limited-field radiotherapy. In some clinical trials, radiotherapy has been omitted. We evaluated 364 patients with stage I-IIA cHL treated between 1999 and 2005. Patients were treated with two or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) according to presence of risk factors, followed by 30 Gy limited-field (reduced compared to involved-field) radiotherapy. After a median follow-up of 16 years for survival, freedom from progression at five and ten years was 93% and overall survival at 5 and 10 years was 98% and 96%, respectively. Only two relapses, out of 27, occurred after more than 5 years. There was no excess mortality compared to the general population. Of the analysed subgroups, only patients with progression within five years showed significant excess mortality. The absence of excess mortality questions the concept of omitting radiotherapy after short-term chemotherapy, a strategy that has been associated with an elevated risk of relapse but not yet with a proven reduced long-term excess mortality.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2020
Nyckelord
limited stage, hodgkin lymphoma, relative survival
Nationell ämneskategori
Hematologi
Identifikatorer
urn:nbn:se:umu:diva-169098 (URN)10.1111/bjh.16232 (DOI)000516520300015 ()31612478 (PubMedID)
Tillgänglig från: 2020-03-20 Skapad: 2020-03-20 Senast uppdaterad: 2020-03-20Bibliografiskt granskad
Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., . . . Ferme, C. (2017). First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma [Letter to the editor]. Bone Marrow Transplantation, 52(2), 310-312
Öppna denna publikation i ny flik eller fönster >>First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma
Visa övriga...
2017 (Engelska)Ingår i: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 52, nr 2, s. 310-312Artikel i tidskrift, Letter (Refereegranskat) Published
Ort, förlag, år, upplaga, sidor
NATURE PUBLISHING GROUP, 2017
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:umu:diva-133455 (URN)10.1038/bmt.2016.271 (DOI)000394134300025 ()27892946 (PubMedID)
Tillgänglig från: 2017-04-12 Skapad: 2017-04-12 Senast uppdaterad: 2018-06-09Bibliografiskt granskad
Mansouri, L., Noerenberg, D., Young, E., Mylonas, E., Abdulla, M., Frick, M., . . . Damm, F. (2016). Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 128(23), 2666-2670
Öppna denna publikation i ny flik eller fönster >>Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
Visa övriga...
2016 (Engelska)Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 128, nr 23, s. 2666-2670Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

We recently reported a truncating deletion in the NFKBIE gene, which encodes IkB epsilon, a negative feedback regulator of NF-kB, in clinically aggressive chronic lymphocytic leukemia (CLL). Because preliminary data indicate enrichment of NFKBIE aberrations in other lymphoid malignancies, we screened a large patient cohort (n = 1460) diagnosed with different lymphoid neoplasms. While NFKBIE deletions were infrequent in follicular lymphoma, splenic marginal zone lymphoma, and T-cell acute lymphoblastic leukemia (< 2%), slightly higher frequencies were seen in diffuse large B- cell lymphoma, mantle cell lymphoma, and primary central nervous system lymphoma (3% to 4%). In contrast, a remarkably high frequency of NFKBIE aberrations (46/203 cases [22.7%]) was observed in primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (3/11 cases [27.3%]). NFKBIE-deleted PMBL patients were more often therapy refractory (P =.022) and displayed inferior outcome compared with wild- type patients (5-year survival, 59% vs 78%; P = .034); however, they appeared to benefit from radiotherapy P = .022) and rituximab-containing regimens (P = .074). NFKBIE aberrations remained an independent factor in multivariate analysis (P =.003) and when restricting the analysis to immunochemotherapy-treated patients (P = .008). Whole-exome sequencing and gene expression profiling verified the importance of NF-kB deregulation in PMBL. In summary, we identify NFKBIE aberrations as a common genetic event across B-cell malignancies and highlight NFKBIE deletions as a novel poor-prognostic marker in PMBL.

Nationell ämneskategori
Cancer och onkologi Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:umu:diva-131885 (URN)10.1182/blood-2016-03-704528 (DOI)000392652300015 ()27670424 (PubMedID)
Tillgänglig från: 2017-02-24 Skapad: 2017-02-24 Senast uppdaterad: 2018-11-14Bibliografiskt granskad
Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., . . . Ferme, C. (2016). STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN'S LYMPHOMA. Paper presented at 10th International Symposium on Hodgkin Lymphoma, Cologne, GERMANY, OCT 22-25, 2016. Haematologica, 101(S5), 50-50, Article ID P091.
Öppna denna publikation i ny flik eller fönster >>STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN'S LYMPHOMA
Visa övriga...
2016 (Engelska)Ingår i: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 101, nr S5, s. 50-50, artikel-id P091Artikel i tidskrift, Meeting abstract (Refereegranskat) Published
Nationell ämneskategori
Hematologi
Identifikatorer
urn:nbn:se:umu:diva-131669 (URN)000392549000117 ()
Konferens
10th International Symposium on Hodgkin Lymphoma, Cologne, GERMANY, OCT 22-25, 2016
Anmärkning

Supplement: 5, Meeting Abstract: P091

Tillgänglig från: 2017-02-23 Skapad: 2017-02-23 Senast uppdaterad: 2018-06-09Bibliografiskt granskad
Junlen, H. R., Peterson, S., Kimby, E., Lockmer, S., Linden, O., Nilsson-Ehle, H., . . . Wahlin, B. E. (2015). Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia, 29(3), 668-676
Öppna denna publikation i ny flik eller fönster >>Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
Visa övriga...
2015 (Engelska)Ingår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 29, nr 3, s. 668-676Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 to 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy and clinical risk factors. Overall and relative survivals were estimated by calendar periods (2000-2002, 2003-2007 and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003-2010 was 92%, 83%, 78% and 64% in the age groups 18-49, 50-59, 60-69 and. 70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages.

Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:umu:diva-102466 (URN)10.1038/leu.2014.251 (DOI)000350734300016 ()25151959 (PubMedID)
Tillgänglig från: 2015-05-19 Skapad: 2015-04-26 Senast uppdaterad: 2018-06-07Bibliografiskt granskad
Kolstad, A., Madsbu, U., Dahle, J., Stokke, C., Bach-Gansmo, T., Londalen, A. M., . . . Holte, H. (2014). A Phase I Study of (177)lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+Non-Hodgkin's B Cell Lymphoma. Blood, 124(21)
Öppna denna publikation i ny flik eller fönster >>A Phase I Study of (177)lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+Non-Hodgkin's B Cell Lymphoma
Visa övriga...
2014 (Engelska)Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 124, nr 21Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:umu:diva-101419 (URN)000349242702165 ()
Tillgänglig från: 2015-04-29 Skapad: 2015-03-30 Senast uppdaterad: 2018-06-07Bibliografiskt granskad
Junlen, H. R., Peterson, S., Kimby, E., Lockmer, S., Linden, O., Nilsson-Ehle, H., . . . Wahlin, B. E. (2014). Follicular Lymphoma Survival in Sweden in the Rituximab Era. Paper presented at 56th ASH Annual Meeting & Exposition, December 6-9, 2015, San Francisco, FL. Blood, 124(21)
Öppna denna publikation i ny flik eller fönster >>Follicular Lymphoma Survival in Sweden in the Rituximab Era
Visa övriga...
2014 (Engelska)Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 124, nr 21Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:umu:diva-101422 (URN)000349242701039 ()
Konferens
56th ASH Annual Meeting & Exposition, December 6-9, 2015, San Francisco, FL
Tillgänglig från: 2015-04-02 Skapad: 2015-03-30 Senast uppdaterad: 2018-06-07Bibliografiskt granskad
Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., . . . Eriksson, M. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology, 24(5), 1385-1392
Öppna denna publikation i ny flik eller fönster >>Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Visa övriga...
2013 (Engelska)Ingår i: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 24, nr 5, s. 1385-1392Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Nyckelord
age-adjusted IPI, central nervous system, diffuse large B-cell lymphoma, intensive chemotherapy, prophylaxis
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:umu:diva-71593 (URN)10.1093/annonc/mds621 (DOI)000318105000034 ()
Tillgänglig från: 2013-06-05 Skapad: 2013-06-04 Senast uppdaterad: 2018-06-08Bibliografiskt granskad
Kimby, E., Östenstad, B., Brown, P. d., Holte, H. J., Hagberg, H., Erlanson, M., . . . Sundström, C. (2012). Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. Paper presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), DEC 08-11, 2012, Atlanta, GA. Blood, 120(21)
Öppna denna publikation i ny flik eller fönster >>Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
Visa övriga...
2012 (Engelska)Ingår i: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 120, nr 21Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Ort, förlag, år, upplaga, sidor
American Society of Hematology, 2012
Nationell ämneskategori
Hematologi
Identifikatorer
urn:nbn:se:umu:diva-67072 (URN)000313838900165 ()
Konferens
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), DEC 08-11, 2012, Atlanta, GA
Tillgänglig från: 2013-03-15 Skapad: 2013-03-12 Senast uppdaterad: 2018-06-08Bibliografiskt granskad
Organisationer

Sök vidare i DiVA

Visa alla publikationer